gemcitabine has been researched along with Sensitivity and Specificity in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.76) | 18.2507 |
| 2000's | 40 (63.49) | 29.6817 |
| 2010's | 17 (26.98) | 24.3611 |
| 2020's | 3 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Acramel, A; Chouquet, T; Goldwirt, L; Jouenne, F; Mourah, S; Plé, A; Sauvageon, H | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Chen, W; Gao, S; Gong, X; Liang, Y; Liu, K; Yang, L; Zhang, F | 1 |
| Chang, Q; Peng, Y; Sun, J; Wang, G; Wang, W; Zhang, X; Zhou, F; Zhou, Y | 1 |
| Aa, L; Fei, F; Hao, K; Jiang, W; Liu, J; Lu, L; Pei, X; Peng, Y; Sun, Y; Wang, G; Wang, J; Zhen, L | 1 |
| Bahra, M; Neumann, CCM; Pratschke, J; Reutzel-Selke, A; Sauer, IM; Schmuck, RB; Seidel, E; von Hörschelmann, E | 1 |
| Hong, D; Hong, W; Kou, JY; Mao, WM; Su, D; Wang, K; Wang, XJ; Xie, FJ; Yu, XM; Zhang, YP | 1 |
| Lee, LB; Ruterbories, KJ; Schmalz, CA; Torchia, J; Wickremsinhe, ER | 1 |
| Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Bachet, JB; Cros, J; Demetter, P; Fléjou, JF; Maréchal, R; Svrcek, M | 1 |
| Chio-Srichan, S; Hahnvajanawong, C; Heraud, P; Jearanaikoon, P; Leelayuwat, C; Limpaiboon, T; Tippayawat, P; Wongwattanakul, M | 1 |
| Saif, MW | 1 |
| Debus, J; Jensen, A; Weber, KJ | 1 |
| Hollender, J; Kovalova, L; McArdell, CS | 1 |
| Hoimes, CJ; Saif, MW; Strimpakos, AS | 1 |
| Aoshima, K; Kadowaki, T; Oda, Y; Tanaka, M; Tanaka, S; Uehara, T; Yokoi, A | 1 |
| Allen-Auerbach, MS; Benz, MR; Chow, K; Czernin, J; Dry, SM; Eckardt, JJ; Eilber, FC; Elashoff, D; Evilevitch, V; Phelps, ME; Tap, WD; Weber, WA | 1 |
| Barthet, M; Calvo, EL; Dagorn, JC; Delpero, JR; Iovanna, JL; Legoffic, A | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Booth, CM; Eisenhauer, EA; Ohorodnyk, P | 1 |
| Puglisi, F | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Hikichi, T; Ikeda, T; Imamura, H; Irisawa, A; Obara, K; Ohira, H; Sato, A; Sato, M; Shibukawa, G; Suzuki, R; Takagi, T; Takahashi, Y; Terashima, M; Wakatsuki, T | 1 |
| Hashimoto, S; Hirai, Y; Kawago, M; Naito, K; Nakamura, R; Nishiguchi, H; Ohta, F; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Brody, JR; Witkiewicz, AK; Yeo, CJ | 1 |
| Chang, YC; Chen, CM; Chih-Hsin Yang, J; Hsu, HH; Hu, FC; Ting-Fang Shih, T; Tseng, WY; Yang, PC; Yu, CJ | 1 |
| Barlev, A; Bray, S; Butt, Z; Cella, D; Fuchs, CS; Kindler, HL; Oglesby, A | 1 |
| Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M | 1 |
| Grem, JL; Keith, B; Xu, Y | 2 |
| Baay, MF; de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Aksoy, Y; Kadioğlu, YY; Yilmaz, B | 1 |
| Albain, KS; Cheng, C; Chiu, A; Doroshow, JH; Frankel, P; Gandara, D; Juhasz, A; Lenz, HJ; Longmate, J; Margolin, K; Newman, EM; Rivera, H; Synold, T; Vishwanath, R; Wilczynski, S; Yen, Y | 1 |
| Goh, BC; Lee, HS; Noordhuis, P; Peters, GJ; Wang, LZ | 1 |
| Coker, A; Kamer, E; Ozer, E; Ozkara, E; Ozzeybek, T; Sevinç, AI | 1 |
| Codacci-Pisanelli, G; Kroep, JR; Loves, W; Peters, GJ; Sigmond, J | 1 |
| Abbruzzese, JL; Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP | 1 |
| Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY | 1 |
| Abbruzzese, JL; Coombes, KR; Fidler, IJ; Hamilton, SR; Hawke, D; Kobayashi, R; Koomen, J; Li, D; Shih, LC; Yokoi, K | 1 |
| Peterson, JA; Risley, DS; Yang, WQ | 1 |
| Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P | 1 |
| Buesa, JM; Esteban, E; Gión, MO; Losa, R; Sierra, MI | 1 |
| Henson, R; Jiang, J; Lang, M; Maheshwari, S; Mendell, JT; Meng, F; Patel, T; Schmittgen, TD; Wehbe, H | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Nishi, R; Ueda, T; Yamauchi, T | 1 |
| Giaccone, G; Honeywell, R; Laan, AC; Peters, GJ; Ruiter, R; Strocchi, E; van Groeningen, CJ | 1 |
| Beijnen, JH; Hillebrand, MJ; Jansen, RS; Perkins, EJ; Rosing, H; Schellens, JH; Veltkamp, SA; Wickremsinhe, ER | 1 |
| Dranitsaris, G; Gascon, P; Lau, C; Ludwig, H; Van Belle, S; Verma, S; Vincent, M | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Boeck, S; Heinemann, V; Holdenrieder, S; Schulz, C; Stieber, P; Weckbach, S | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Beijnen, JH; Rosing, H; Schellens, JH; Thijssen, B; Vainchtein, LD | 1 |
| Cerny, T; Früh, M; Lanz, C; Lauterburg, BH; Thormann, W | 1 |
| Caffo, O; D'Incalci, M; Galligioni, E; Marangon, E; Sala, F; Zucchetti, M | 1 |
| Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS | 1 |
| Copley-Merriman, C; Corral, J; Dorr, FA; King, K; McDonald, RC; Voi, M; Whiteside, R | 1 |
| Boeck, G; Egle, A; Geisen, F; Greil, R; Gruber, J; Konwalinka, G; Sgonc, R; Villunger, A | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 1 |
3 review(s) available for gemcitabine and Sensitivity and Specificity
| Article | Year |
|---|---|
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity | 2011 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
7 trial(s) available for gemcitabine and Sensitivity and Specificity
| Article | Year |
|---|---|
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2014 |
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast; Breast Neoplasms; Cisplatin; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; DNA, Complementary; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Sensitivity and Specificity; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2003 |
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Endpoint Determination; Gemcitabine; Humans; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2005 |
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Lung Neoplasms; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Savings; Deoxycytidine; Direct Service Costs; Drug Costs; Etoposide; Female; Gemcitabine; Health Services Research; Hospital Costs; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Models, Economic; Monte Carlo Method; Oncology Service, Hospital; Sensitivity and Specificity; United States | 1996 |
54 other study(ies) available for gemcitabine and Sensitivity and Specificity
| Article | Year |
|---|---|
Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Environmental Pollutants; Gemcitabine; Occupational Exposure; Paclitaxel; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Deoxycytidine; Etoposide; Gemcitabine; Humans; Linear Models; Lung Neoplasms; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vinblastine; Vinorelbine | 2017 |
Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS.
Topics: Animals; Carbamates; Chromatography, Liquid; Deoxycytidine; Gemcitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2018 |
Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Survival; Coculture Techniques; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Risk Factors; Sensitivity and Specificity; Stromal Cells; Tumor Cells, Cultured | 2018 |
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2013 |
High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Deoxyuridine; Floxuridine; Gemcitabine; Humans; Prodrugs; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Rabbits; Sensitivity and Specificity; Tissue Array Analysis | 2015 |
Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Microscopy; Neoplasm Transplantation; Phenotype; Sensitivity and Specificity; Spectroscopy, Fourier Transform Infrared; Synchrotrons | 2017 |
Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Meta-Analysis as Topic; Mucin-1; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Rate | 2008 |
S-phase cell-specific modification by gemcitabine of PFGE-analyzed radiation-induced DNA fragmentation and rejoining.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; DNA; DNA Fragmentation; DNA Repair; Dose-Response Relationship, Drug; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; S Phase; Sensitivity and Specificity | 2008 |
Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry.
Topics: Adsorption; Chromatography, Liquid; Cytostatic Agents; Deoxycytidine; Drug Residues; Floxuridine; Fluorouracil; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Linear Models; Models, Molecular; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2009 |
Therapeutic tools in pancreatic cancer.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Haptoglobins; Humans; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity | 2009 |
Quantitative phosphorus metabolomics using nanoflow liquid chromatography-tandem mass spectrometry and culture-derived comprehensive global internal standards.
Topics: Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Metabolomics; Methotrexate; Phosphorus; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2009 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromosome Mapping; Chromosomes, Human; Chromosomes, Human, X; Comparative Genomic Hybridization; Deoxycytidine; Drug Resistance; Gemcitabine; Genetic Variation; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2009 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neoplasms; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Periodicals as Topic; Sensitivity and Specificity; Survival Analysis; Total Quality Management; Treatment Outcome | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration.
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Cell Survival; Cells, Cultured; Deoxycytidine; Disease-Free Survival; Endosonography; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2011 |
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2011 |
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Outcome Assessment; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Symptom Assessment | 2013 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured | 2002 |
Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies.
Topics: Breast Neoplasms; Colonic Neoplasms; Colony-Forming Units Assay; Colorimetry; Combined Modality Therapy; Deoxycytidine; Fluorescent Dyes; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Rhodamines; Sensitivity and Specificity; Tumor Cells, Cultured | 2003 |
Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Urinary Bladder Neoplasms | 2003 |
An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Sensitivity and Specificity | 2003 |
Effects of intraperitoneal administration of gemcitabine and paclitaxel on hepatic regeneration in rats.
Topics: Animals; Biopsy, Needle; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Immunohistochemistry; Injections, Intraperitoneal; Liver; Liver Function Tests; Liver Regeneration; Male; Paclitaxel; Rats; Rats, Inbred Strains; Sensitivity and Specificity | 2003 |
Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.
Topics: Adult; Antimetabolites, Antineoplastic; Deamination; Deoxycytidine; Gemcitabine; Humans; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Esophageal Neoplasms; Gemcitabine; Gene Expression Profiling; Humans; Light; Phosphorylation; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Transplantation, Heterologous; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate | 2005 |
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Staging; Neoplasms, Experimental; Pancreatic Neoplasms; Random Allocation; Sensitivity and Specificity; Serum Amyloid A Protein; Transplantation, Heterologous | 2005 |
Analysis of mannitol in pharmaceutical formulations using hydrophilic interaction liquid chromatography with evaporative light-scattering detection.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Drug Compounding; Drug Stability; Excipients; Gemcitabine; Light; Mannitol; Scattering, Radiation; Sensitivity and Specificity; Solvents | 2006 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Monocytes; Ovarian Neoplasms; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2006 |
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
Topics: Animals; Apoptosis; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; MicroRNAs; Oligonucleotide Array Sequence Analysis; Probability; Reverse Transcriptase Polymerase Chain Reaction; Sampling Studies; Sensitivity and Specificity; Transfection; Transplantation, Heterologous | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Gemcitabine; HL-60 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sensitivity and Specificity | 2006 |
Analysis of deoxycytidine accumulation in gemcitabine treated patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemistry, Clinical; Chromatography; Deoxycytidine; Gemcitabine; Humans; Mass Spectrometry; Models, Biological; Models, Chemical; Sensitivity and Specificity; Time Factors | 2006 |
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Topics: Anions; Antimetabolites, Antineoplastic; Calibration; Chromatography, Liquid; Deoxycytidine; Gemcitabine; Humans; Leukocyte Count; Leukocytes, Mononuclear; Proteins; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2006 |
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy.
Topics: Aged; Analysis of Variance; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Europe; False Positive Reactions; Female; Gemcitabine; Hemoglobins; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Palliative Care; Platinum Compounds; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Complex Mixtures; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2007 |
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.
Topics: Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Calibration; Chemistry, Clinical; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Male; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Serum | 2007 |
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured | 2008 |
2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Topics: 2-Chloroadenosine; Antimetabolites, Antineoplastic; Apoptosis; Biotin; Deoxyadenosines; Deoxycytidine; Deoxyuracil Nucleotides; Dexamethasone; DNA Damage; Drug Resistance; Gemcitabine; Glucocorticoids; Hematopoietic Stem Cells; Humans; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sensitivity and Specificity; Staining and Labeling; Steroids; Tumor Cells, Cultured | 1996 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |